Wealthfront Advisers’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.63M | Buy |
40,124
+3,692
| +10% | +$309K | 0.01% | 501 |
|
|
2026
Q1 | $2.92M | Buy |
36,432
+4,116
| +13% | +$339K | 0.01% | 540 |
|
|
2025
Q4 | $2.75M | Buy |
32,316
+2,654
| +9% | +$218K | 0.01% | 534 |
|
|
2025
Q3 | $2.31M | Buy |
29,662
+2,083
| +8% | +$163K | 0.01% | 563 |
|
|
2025
Q2 | $2.16M | Buy |
27,579
+2,566
| +10% | +$191K | 0.01% | 558 |
|
|
2025
Q1 | $1.81M | Buy |
25,013
+3,065
| +14% | +$219K | ﹤0.01% | 559 |
|
|
2024
Q4 | $1.62M | Buy |
21,948
+5,846
| +36% | +$409K | ﹤0.01% | 567 |
|
|
2024
Q3 | $1.06M | Sell |
16,102
-19,359
| -55% | -$1.41M | ﹤0.01% | 633 |
|
|
2024
Q2 | $3.28M | Buy |
35,461
+1
| +0% | +$89 | 0.01% | 364 |
|
|
2024
Q1 | $3.39M | Buy |
35,460
+321
| +0.9% | +$27K | 0.01% | 364 |
|
|
2023
Q4 | $2.68M | Sell |
35,139
-20,353
| -37% | -$1.42M | 0.01% | 395 |
|
|
2023
Q3 | $3.84M | Buy |
55,492
+18,145
| +49% | +$1.46M | 0.02% | 267 |
|
|
2023
Q2 | $3.52M | Buy |
37,347
+1,580
| +4% | +$137K | 0.01% | 290 |
|
|
2023
Q1 | $2.96M | Buy |
35,767
+3,075
| +9% | +$242K | 0.01% | 324 |
|
|
2022
Q4 | $2.44M | Sell |
32,692
-4,253
| -12% | -$328K | 0.01% | 353 |
|
|
2022
Q3 | $3.05M | Buy |
36,945
+1,482
| +4% | +$143K | 0.02% | 275 |
|
|
2022
Q2 | $3.37M | Sell |
35,463
-1,232
| -3% | -$128K | 0.02% | 258 |
|
|
2022
Q1 | $4.32M | Buy |
36,695
+6,413
| +21% | +$719K | 0.02% | 230 |
|
|
2021
Q4 | $3.92M | Buy |
30,282
+4,004
| +15% | +$467K | 0.02% | 235 |
|
|
2021
Q3 | $2.98M | Buy |
26,278
+3,956
| +18% | +$452K | 0.01% | 255 |
|
|
2021
Q2 | $2.31M | Buy |
22,322
+2,452
| +12% | +$231K | 0.01% | 275 |
|
|
2021
Q1 | $1.66M | Buy |
19,870
+148
| +0.8% | +$12.5K | 0.01% | 306 |
|
|
2020
Q4 | $1.8M | Sell |
19,722
-482
| -2% | -$40K | 0.01% | 249 |
|
|
2020
Q3 | $1.61M | Sell |
20,204
-361
| -2% | -$28.2K | 0.01% | 226 |
|
|
2020
Q2 | $1.42M | Sell |
20,565
-477
| -2% | -$33.9K | 0.01% | 241 |
|
|
2020
Q1 | $1.32M | Sell |
21,042
-7,575
| -26% | -$546K | 0.01% | 209 |
|
|
2019
Q4 | $2.23M | Buy |
28,617
+1,314
| +5% | +$103K | 0.02% | 158 |
|
|
2019
Q3 | $2M | Buy |
27,303
+1,518
| +6% | +$107K | 0.02% | 170 |
|
|
2019
Q2 | $1.59M | Sell |
25,785
-684
| -3% | -$41.4K | 0.01% | 187 |
|
|
2019
Q1 | $1.69M | Buy |
26,469
+6,744
| +34% | +$385K | 0.02% | 176 |
|
|
2018
Q4 | $1.01M | Buy |
+19,725
| New | +$998K | 0.01% | 245 |
|
Other funds holding EW
WT
Wealthfront Advisers's EW Position: Q2 2026 in Review
Wealthfront Advisers increased its Edwards Lifesciences (EW) stake by 10% in Q2 2026, buying an estimated $309K and bringing the position to 40,124 shares worth $3.63M. The position accounts for 0.01% of the portfolio, ranked #501.
Wealthfront Advisers first reported a position in EW in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.32M in Q1 2022. 1,006 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Wealthfront Advisers held 40,124 shares of Edwards Lifesciences worth $3.63M as of Q2 2026.
- Wealthfront Advisers bought 3,692 Edwards Lifesciences shares in Q2 2026, an estimated $309K.
- Edwards Lifesciences made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #501 holding.
- Wealthfront Advisers first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Edwards Lifesciences position peaked at $4.32M in Q1 2022.
- 1,006 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.